Bradley Ronald H, Barkin Robert L, Jerome John, DeYoung Kevin, Dodge Charles William
Total Health Care of Michigan, P.C., East Lansing, MI 48823, USA.
Am J Ther. 2003 Sep-Oct;10(5):318-23. doi: 10.1097/00045391-200309000-00003.
This was an open-label, single-center study of the long-term efficacy and effectiveness of venlafaxine extended release (XR) in the treatment of chronic pain and depression in outpatients. All patients have been diagnosed with major depressive disorder (MDD) of various types, with or without chronic pain, and had previously failed treatment with either tricyclic antidepressants (TCAs) or selective serotonin reuptake inhibitors (SSRIs).
Efficacy of treatment was determined using the 21-item Hamilton Rating Scale for Depression (HAMD-21), the Visual Analogue Scale (VAS) for the evaluation of pain, and a 12-item quality of life scale (QOL). Patients were treated in an unblended open trial for 1 year with 150 mg or more of venlafaxine XR once daily.
After 1 year of treatment, 21-item Hamilton Rating Scale for Depression, Visual Analogue Scale, and quality of life scores were significantly improved from permanent baseline scores.
These data show long-term efficacy and effectiveness of venlafaxine XR, a serotonin (5-HT) and norepinephrine (NE) and dopamine (DA) reuptake inhibitor antidepressant agent, having analgesic properties.
这是一项开放标签、单中心研究，旨在评估文拉法辛缓释剂（XR）治疗门诊患者慢性疼痛和抑郁症的长期疗效和有效性。所有患者均被诊断为各种类型的重度抑郁症（MDD），伴有或不伴有慢性疼痛，且此前使用三环类抗抑郁药（TCA）或选择性5-羟色胺再摄取抑制剂（SSRI）治疗均失败。
使用21项汉密尔顿抑郁评定量表（HAMD-21）、视觉模拟量表（VAS）评估疼痛，以及12项生活质量量表（QOL）来确定治疗效果。患者在非混合开放试验中接受为期1年的治疗，每日一次服用150毫克或更多的文拉法辛XR。
治疗1年后，21项汉密尔顿抑郁评定量表、视觉模拟量表和生活质量评分较基线评分有显著改善。
这些数据表明，具有镇痛特性的5-羟色胺（5-HT）、去甲肾上腺素（NE）和多巴胺（DA）再摄取抑制剂抗抑郁药文拉法辛XR具有长期疗效和有效性。
